asa guidelines for glp-1 agonists Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Glucagon-Like Peptide-1 Receptor Agonists in

10.1371/journal.pone.0012226 30

Bianchi R, Cervellini I, Porretta-Serapiglia C, et al

Collaborative decision-making between patients, endocrinologists or primary care providers, and ophthalmologists ensures that GLP-1 therapy is implemented safely with appropriate safeguards for ocular health

In particular, malignant cells can modify their energy metabolism in response to a challenging environment, allowing tumor cells to survive and spread (Lin et al., 2020)

Primary outcome The primary outcome, major adverse cardiovascular events (MACE), was reported in all 11 included studies, comprising of 91,490 participants with 4386 MACE events in the intervention group and 4884 MACE events in the placebo group

Akt, serine/threonine kinase B